EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Biomarkers of Cardioembolic Stroke in Thrombus Composition: Diagnostic Value of DNA and Fibrin Content

Jéromine Fasille iD, Mialitiana Solo Nomenjanahary, Dorothée Faille iD, Capucine Habay, Laurine Bedoucha iD, Maeva Kyheng, Julien Labreuche, Arturo Consoli, Bertrand Lapergue, Michel Piotin, Raphael Blanc, Benoit Ho-Tin-Noé und 4 weitere

European Journal of Neurology · 2026

DOI: 10.1111/ene.70484 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Neurology, 2026. Verfasst von Jéromine Fasille und 15 weiteren Autor:innen. Beteiligte Einrichtung: Université de Paris Cité, Optimisation Thérapeutique en Neuropharmacologie, U1144 Institut National de la Santé et de la Recherche Médicale (INSERM),…. Hauptthemen laut MEDLINE: Embolic Stroke, Fibrin Fibrinogen Degradation Products, Thrombosis, DNA. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Purpose Cryptogenic strokes, accounting for 25%–40% of ischemic strokes, represent a major challenge in secondary prevention due to their uncertain etiology and high recurrence risk. Identifying biomarkers to reliably distinguish cardioembolic (CE) strokes among embolic strokes of undetermined source (ESUS) could help guide therapeutic decisions. Previous studies have indicated thrombus DNA content as a potential biomarker of CE stroke etiology, but direct quantification of fibrin, another key component, has not been adequately explored.

Methods

We analyzed thrombi collected from 186 ischemic stroke patients undergoing endovascular treatment between 2019 and 2023. Thrombi were processed using a quantitative method based on ex vivo tPA‐mediated fibrinolysis followed by mechanical homogenization. Stroke etiology was classified according to TOAST criteria: 40% cardioembolic, 24% non‐cardioembolic (large artery atherosclerosis or dissection), and 36% ESUS. Biomarker content was correlated with stroke etiology, and the diagnostic performance of DNA and fibrin (D‐dimer) content was evaluated.

Results

Cardioembolic thrombi contained significantly higher levels of DNA (median [IQR]: 325.3 [177–484] ng/mg) and D‐dimer (17.5 [9.1–23.8] μg/mg) compared to non‐cardioembolic thrombi (DNA: 128 [76.4–263] ng/mg; D‐dimer: 11.4 [6.8–13.2] μg/mg), with no significant differences observed in heme or GPVI content. The combined use of thrombus DNA and fibrin (D‐dimer) content provided good discrimination between CE and non‐CE thrombi, with an area under the ROC curve of 0.79 (95% CI, 0.70–0.87).

Conclusion

DNA and fibrin content in thrombi are promising biomarkers for identifying cardioembolic stroke etiology. Prospective studies should evaluate their use in selecting ESUS patients who may benefit from anticoagulant therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Embolic StrokeFibrin Fibrinogen Degradation ProductsThrombosisDNAFibrinStrokeHumansBiomarkersFemaleMaleAgedMiddle AgedAged, 80 and overHeart Diseases

Stichwörter der Autor:innen

DNAESUSbiomarkerfibrinsecondary prevention

Substanzen

BiomarkersFibrin Fibrinogen Degradation ProductsDNAFibrinfibrin fragment D

Autor:innen und Institutionen

  • Université de Paris Cité, Optimisation Thérapeutique en Neuropharmacologie, U1144 Institut National de la Santé et de la Recherche Médicale (INSERM), FHU Neurovasc, Paris, France.
  • Sorbonne Université, Paris, France.
  • Univ. Lille, CHU Lille, EA 2694, Santé Publique: épidémiologie et qualité Des Soins, France.
  • Department of Stroke Centre and Diagnostic and Interventional Neuroradiology, University of Versailles and Saint Quentin en Yvelines, Foch Hospital, Suresnes, France.
  • Department of Interventional Neuro Radiology, Rothschild Foundation Hospital, Paris, France.
  • Department of Neurology, Université Paris Cité, AP-HP, Hôpital Lariboisière, Paris, France.

ORCID-Profile: Jéromine Fasille, Dorothée Faille, Laurine Bedoucha, Lucas Di Meglio

Zitieren

APA

Fasille, J., Nomenjanahary, M. S., Faille, D., Habay, C., Bedoucha, L., Kyheng, M., Labreuche, J., Consoli, A., Lapergue, B., Piotin, M., Blanc, R., Ho-Tin-Noé, B., Mazighi, M., Desilles, J. P., Di Meglio, L., & Compo CLOT Study Group (2026). Biomarkers of Cardioembolic Stroke in Thrombus Composition: Diagnostic Value of DNA and Fibrin Content. European Journal of Neurology. https://doi.org/10.1111/ene.70484

Vancouver

Fasille J, Nomenjanahary MS, Faille D, Habay C, Bedoucha L, Kyheng M, et al. Biomarkers of Cardioembolic Stroke in Thrombus Composition: Diagnostic Value of DNA and Fibrin Content. European Journal of Neurology. 2026. doi:10.1111/ene.70484

BibTeX
@article{Fasille2026,
  author = {Fasille, Jéromine and Nomenjanahary, Mialitiana Solo and Faille, Dorothée and Habay, Capucine and Bedoucha, Laurine and Kyheng, Maeva and Labreuche, Julien and Consoli, Arturo and Lapergue, Bertrand and Piotin, Michel and Blanc, Raphael and Ho-Tin-Noé, Benoit and Mazighi, Mikael and Desilles, Jean Philippe and Di Meglio, Lucas and Compo CLOT Study Group, Compo CLOT Study Group},
  title = {Biomarkers of Cardioembolic Stroke in Thrombus Composition: Diagnostic Value of DNA and Fibrin Content},
  journal = {European Journal of Neurology},
  year = {2026},
  doi = {10.1111/ene.70484}
}
Kostenlos starten →